» Articles » PMID: 33492094

Estimates of the Prevalence and Incidence of Chlamydia and Gonorrhea Among US Men and Women, 2018

Overview
Journal Sex Transm Dis
Date 2021 Jan 25
PMID 33492094
Citations 31
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The most recent prevalence and incidence estimates for chlamydia and gonorrhea, the 2 most reported sexually transmitted infections in the United States, were for 2008. We present updated estimates of the number of prevalent and incident chlamydial and gonococcal infections for 2018.

Methods: We estimated chlamydial prevalence directly from the 2015 to 2018 cycles of the National Health and Nutrition Examination Survey and chlamydial incidence using a mathematical model primarily informed by National Health and Nutrition Examination Survey and case report data. Total and antimicrobial-resistant gonococcal prevalence and incidence were estimated using mathematical models primarily informed by case report and Gonococcal Isolate Surveillance Program data. Estimates were calculated for the total population, all women, and all men aged 15 to 39 years, stratified by age group. Primary estimates represent medians and uncertainty intervals represent the 25th (Q1) and 75th (Q3) percentiles of the empirical frequency distributions of prevalence and incidence for each infection.

Results: Among persons aged 15 to 39 years in the United States in 2018, we estimate 2.35 (Q1, 2.20; Q3, 2.51) million prevalent and 3.98 (Q1, 3.77; Q3, 4.22) million incident chlamydial infections, and an estimated 209,000 (Q1, 183,000; Q3, 241,000) prevalent and 1.57 (Q1, 1.44; Q3, 1.72) million incident gonococcal infections. Of all gonococcal infections, there were 107,000 (Q1, 94,000; Q3, 124,000) prevalent and 804,000 (Q1, 738,000; Q3, 883,000) incident infections demonstrating antimicrobial resistance or elevated minimum inhibitory concentrations to selected antibiotics.

Conclusions: Chlamydia and gonorrhea were very common in the United States in 2018. Estimates show that more than 800,000 newly acquired gonococcal infections in 2018 demonstrated resistance or elevated minimum inhibitory concentrations to currently or previously recommended antibiotics.

Citing Articles

Impact of a potential Chlamydia vaccine in the USA: mathematical modelling analyses.

Makhoul M, Ayoub H, Awad S, Chemaitelly H, Abu-Raddad L BMJ Public Health. 2025; 2(1):e000345.

PMID: 40018092 PMC: 11812766. DOI: 10.1136/bmjph-2023-000345.


L-Serovar Rectal Chlamydia trachomatis in Patients Who Were Male-Assigned at Birth Attending Two Sexual Health Clinics, Baltimore, Maryland 2009-2016.

Hamill M, Deng Z, Hardick J, Tobias S, Page K, Quinn T Sex Transm Dis. 2025; 52(3):169-175.

PMID: 39902832 PMC: 11801234. DOI: 10.1097/OLQ.0000000000002097.


A systematic review to identify research gaps in studies modeling MenB vaccinations against Neisseria infections.

Metelmann S, Thompson A, Donten A, Oke S, Sun S, Borrow R PLoS One. 2025; 20(1):e0316184.

PMID: 39746102 PMC: 11694989. DOI: 10.1371/journal.pone.0316184.


Development of a lambda Red based system for gene deletion in Chlamydia.

Wang Y, Suchland R, Hua A, Carrell S, Rockey D, Hybiske K PLoS One. 2024; 19(11):e0311630.

PMID: 39541273 PMC: 11563418. DOI: 10.1371/journal.pone.0311630.


Irradiated whole cell Chlamydia vaccine confers significant protection in a murine genital tract challenge model.

Broder K, Matrosova V, Tkavc R, Gaidamakova E, Ho L, Macintyre A NPJ Vaccines. 2024; 9(1):207.

PMID: 39528548 PMC: 11554809. DOI: 10.1038/s41541-024-00968-z.